Hotline: 86-023-62505954
 
 
Product&Service Products
Contact Us
/ contact us
If you want to consult products, call us:
TEL:
86-023-62505954
FAX:
86-023-62512066
E-mail:
cpri@cpri.com.cn
产品名称:

Product and Manufacture

上市日期: 2017-01-04
Product Details

Chongqing Pharmaceutical Research Institute (Changshou) Co., Ltd. (CPRI), is a reputable R&D-based API manufacturer in China. Held by CPRI., member of Shanghai Fosun Pharmaceutical (group) Co., Ltd. CPRI is dedicated to stable supply of characteristic API to all partners.

 As an important comprehensive pharmaceutical research institute engaged in chemical synthetic drug R&D in China, CPRI has a team over 200 professional researchers, established an integrated R&D system from early-stage development of NEC and genetic API, to pharmaceutical and toxicological evaluation, to clinical trials and cGMP manufacturing. So far, CPRI has filed over 270 Chinese patents, 24 PCT patents and 37 foreign patents. Now 76 Chinese patents and over 20 foreign patents are granted. CPRI commercialized its scientific achievement over 80%, with a total industrial value over RMB 10 billion. CPRI was one of the two companies which first got the Aripiprazole manufacturing license in China in 2004. Moreover, the quality of Iron sucrose is up to original standard and CPRI has developed business relationship with many global corporations. With high quality and experienced registration team, Pemetrexed disodium has been registered in over 50 countries and regions. CPRI has broken the technical bottleneck of Canagliflozin and developed new monohydrate form which is totally different from original crystal form. Besides the API, CPRI also supplies advanced intermediates, being one of the largest suppliers of Rocuronium intermediates in the world.

         As leading manufacturer of API and advanced pharmaceutical intermediates, CPRI’s new plant is compliant with cGMP, ICH, and ISPE standards, covering around 80,000 m2 in national chemical industry park of Changshou district of Chongqing city. With help and support of YaoPharma and Fosunpharma Group, CPRI will be keeping supplying high-quality products to our partners of global market, stepping on the way to state-of-the-art pharmaceutical supplier with international competitiveness. 



Product  Name

CAS No

Indication

Remarks

1

Iron sucrose*

8047-67-4

Anaemia

DMF No.: 18390

2

Canagliflozin*

928672-86-0

Diabetes

DMF No.: 30853

3

Pemetrexed disodium*

150399-23-8

Cancer

EDMF No.: 01122

4

Aripiprazole*

129722-12-9

Schizophrenia

China GMP certified

5

Rocuronium intermediates*

119302-20-4

Muscle Relaxant

Commercial supply

6

Dabigatran etexilate mesylate*

593282-20-3

Thrombosis

Validation finished

7

Abiraterone acetate*

154229-18-2

Cancer

Validation finished

8

Bortezomib*

179324-69-7

Cancer

Validation finished

9

Carfilzomib*

868540-17-4

Cancer

Pilot study

10

Apremilast*

608141-41-9

Psoriasis

Pilot study

11

Ferric carboxymaltose*

9007-72-1

Anaemia

Pilot study

12

Ferric Citrate*

2338-05-8

hyperphosphatemia

Pilot study

13

Palbociclib*

571190-30-2

Cancer

Pilot study

14

Ibrutinib*

936563-96-1

Cancer

Pilot study

15

Lenvatinib*

417716-92-8

Cancer

Lab scale

16

Ferric Maltol*

33725-54-1

Anaemia

Lab scale

17

Ferric Pyrophosphate*

N/A

Anaemia

Lab scale

18

Ferumoxytol*

N/A

Anaemia

Lab scale

* Disclaimer: The information is provided only for R&D Purposes. The information is not and should not constitute an offer for sale in countries or areas where it is not permitted by law.

 

Contact email: sales@cpri.com.cn

Website: www.cpri.cn

Factory Address:  No. 2, The Third Branch Road, Huanan Road,

Changshou Economic & Technological Development District,

Chongqing 401220, China (CHN)

Tel: +86-23-6239279

                                                                                                                                     

 

 




Related Products: / Related Products: More
2017 - 01 - 04
CPRI is committed to offering our customer with broad range of reliable services including contracted R&D of generics, improved drug and innovative drug, CMC research of innovative drugs, pharmaceutical study of quality consistency evaluation for generic drugs and regulatory registration. Meanwhile, methodology development for specific analytical purpose, custom synthesis of API impurities and...
2017 - 01 - 04
We have a professional team engaged in managing clinical research for many years and directly led by a group of experts with in-depth insight in project design, experiment organization and coordination by applying a robust quality management system. They are responsible for preparation and organization of clinical study activities and BE study of new drug product and managed to maintain long-term ...
2017 - 03 - 28
To be add...
 Contact Us
No.565 · NanAnDistrict · ChongQing
Tel: 86-023-62505954
86-023062505956
E-mail:cpri@cpri.com.cn
Copyright ©2005 - 2013 Chongqing Pharmaceutical Research Institute
犀牛云提供企业云服务